Literature DB >> 19122861

The evolving role of nuclear molecular imaging in cancer.

Ka Kurdziel1, G Ravizzini, By Croft, Jl Tatum, Pl Choyke, H Kobayashi.   

Abstract

BACKGROUND: Novel therapies targeted to specific tumor pathways are entering the clinic. The need for in vivo monitoring of resulting molecular changes, particularly with respect to the tumor microenvironment, is growing. Molecular imaging is evolving to include a variety of imaging methods to enable in vivo monitoring of cellular and molecular processes.
OBJECTIVES: This article reviews the emerging role of molecular imaging in the development of improved therapeutic strategies that provide better patient selection for therapeutic personalization (i.e. determine which therapies have the greatest chance of success given the individual patient's disease genetic, and phenotypical profile).
METHODS: In order to illustrate the utility of integrating molecular imaging into therapy development strategies, current and emerging applications of nuclear molecular imaging strategies will be compared with conventional strategies. Proposed methods of integrating molecular imaging techniques into cancer therapeutic development and limitations of these techniques will be discussed. RESULTS/
CONCLUSION: Molecular imaging provides a variety of new tools to accelerate the development of cancer therapies. The recent drive to develop molecular imaging probes and standardize molecular imaging techniques is creating the scaffolding for the evolving paradigm shift to personalized cancer therapy.

Entities:  

Year:  2008        PMID: 19122861      PMCID: PMC2600859          DOI: 10.1517/17530059.2.7.829

Source DB:  PubMed          Journal:  Expert Opin Med Diagn        ISSN: 1753-0059


  96 in total

1.  Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

Authors:  A Sparreboom; A S Planting; R C Jewell; M E van der Burg; A van der Gaast; P de Bruijn; W J Loos; K Nooter; L H Chandler; E M Paul; P S Wissel; J Verweij
Journal:  Anticancer Drugs       Date:  1999-09       Impact factor: 2.248

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 3.  Systems biology in drug discovery.

Authors:  Eugene C Butcher; Ellen L Berg; Eric J Kunkel
Journal:  Nat Biotechnol       Date:  2004-10       Impact factor: 54.908

4.  Systems biology and new technologies enable predictive and preventative medicine.

Authors:  Leroy Hood; James R Heath; Michael E Phelps; Biaoyang Lin
Journal:  Science       Date:  2004-10-22       Impact factor: 47.728

Review 5.  Molecular imaging of cell-mediated cancer immunotherapy.

Authors:  Giovanni Lucignani; Luisa Ottobrini; Cristina Martelli; Maria Rescigno; Mario Clerici
Journal:  Trends Biotechnol       Date:  2006-07-25       Impact factor: 19.536

Review 6.  True tracers: comparing FDG with glucose and FLT with thymidine.

Authors:  Kenneth A Krohn; David A Mankoff; Mark Muzi; Jeanne M Link; Alexander M Spence
Journal:  Nucl Med Biol       Date:  2005-10       Impact factor: 2.408

7.  Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.

Authors:  Edward B Silberstein
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

8.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.

Authors:  V J Lowe; D M DeLong; J M Hoffman; R E Coleman
Journal:  J Nucl Med       Date:  1995-05       Impact factor: 10.057

10.  Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.

Authors:  Kevin P Donahue; Nirav P Shah; Stephanie L Lee; M Elizabeth Oates
Journal:  Radiology       Date:  2008-03       Impact factor: 11.105

View more
  8 in total

1.  Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis.

Authors:  Mojtaba Ghasemi; Iraj Nabipour; Abdolmajid Omrani; Zeinab Alipour; Majid Assadi
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

2.  Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.

Authors:  Jeong Won Lee; Hye Sook Min; Sang Mi Lee; Hyun Woo Kwon; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2015-02-13

Review 3.  Application of Advanced Imaging Modalities in Veterinary Medicine: A Review.

Authors:  Dagmawi Yitbarek; Gashaw Getaneh Dagnaw
Journal:  Vet Med (Auckl)       Date:  2022-05-31

Review 4.  The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.

Authors:  Renata Salgado Fernandes; Carolina de Aguiar Ferreira; Daniel Cristian Ferreira Soares; Anna Margherita Maffione; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2017-09-12       Impact factor: 6.529

Review 5.  Advances in molecular imaging for breast cancer detection and characterization.

Authors:  Jennifer M Specht; David A Mankoff
Journal:  Breast Cancer Res       Date:  2012-03-16       Impact factor: 6.466

6.  PET Use in Cancer Diagnosis, Treatment, and Prognosis.

Authors:  Naresh Damuka; Meghana Dodda; Kiran Kumar Solingapuram Sai
Journal:  Methods Mol Biol       Date:  2022

7.  Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'-deoxy-3'-[18F] fluorothymidine in patients with lung cancer.

Authors:  Xiangcheng Wang; Yulin He; Weina Zhou; Xia Bai; Yiwei Wu; Xuemei Wang; Xiao-Feng Li
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 8.  124 Iodine: a longer-life positron emitter isotope-new opportunities in molecular imaging.

Authors:  Giuseppe Lucio Cascini; Artor Niccoli Asabella; Antonio Notaristefano; Antonino Restuccia; Cristina Ferrari; Domenico Rubini; Corinna Altini; Giuseppe Rubini
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.